Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer
This study is a multi-center, single-arm, open-label phase II clinical trial, aiming to observe and evaluate the perioperative treatment of tislelizumab combined with chemotherapy (CAPOX) in stage II or III colorectal cancer with MSI-H/dMMR Patient efficacy and safety.
MSI-H Colorectal Cancer|Tislelizumab|Oxaliplatin|Capecitabine
DRUG: Tislelizumab
Percentage of Participants With Pathological Complete Response (pCR), After receiving tislelizumab combined with CAPOX neoadjuvant, the rate of pathological complete remission (after neoadjuvant therapy, for those who insist on organ preservation, combined with imaging and endoscopic examination to achieve cCR, and the biopsy result of the microscope is pathological Complete remission can be judged as pCR), Up to 24 months
R0 resection rates, The proportion of patients achieved a complete resection with negative margin., Up to 24 months|Overall survival (OS), Defined as the time from randomization to death from any cause., Up to 36 months|Event-free survival (EFS), Event-free survival is the time from the beginning of enrollment to the occurrence of any event, including death, disease progression, change to chemotherapy, change to chemotherapy, addition of other treatments, and occurrence of fatal or intolerable side effects, Up to 36 months|Incidence of adverse events during the treatment and follow-up (safety), Adverse events will be assessed during treatment and follow-up., until 100 days after last patient last study drug treatment
This study is a multi-center, single-arm, open-label phase II clinical trial, aiming to observe and evaluate the perioperative treatment of tislelizumab combined with chemotherapy (CAPOX) in stage II or III colorectal cancer with MSI-H/dMMR Patient efficacy and safety.